Stopping Cancer Before It Starts

Antiva is developing a novel topical therapeutic for the treatment of oncogenic (high-risk) human papillomavirus (HPV) infections and for the treatment of pre-cancerous cervical lesions caused by HPV in women. Currently, there is no approved treatment for HPV infection; women must wait and see whether their infection clears by itself or progresses to more advanced disease, such as precancerous cervical lesions or cancer. The only treatments available for pre-cancerous cervical lesions are invasive in-office surgical-based options with risks to long-term reproductive health. If successful, our therapy will give women the ability to treat themselves in the privacy of their own homes when their infection is first diagnosed and provide a non-surgical option for women whose disease has progressed to pre-cancerous lesions.

Our passionate, experienced team is dedicated to improving health outcomes and access to care worldwide by developing a simple and convenient non-surgical approach to treat HPV infection and pre-cancerous lesions, supporting the World Health Organization’s global Cervical Cancer Elimination Initiative.